讨论
SeekingBiotech05-23 14:06
F230片 北京康蒂尼药业股份有限公司 肺动脉高压
简介：北京康蒂尼药业股份有限公司创立于2002年,是一家以器官纤维化疾病为核心,集研发、生产、销售于一体的创新药物开发企业。 作为器官纤维化领域的先行者,公司的旗舰产品1.1类新药艾思瑞(呲非尼酮胶囊)是全球唯二已获批且受指南推荐的特发性肺纤维化(IPF)治疗药物,也是国内首款用于治疗IPF的创新药物，2014年成功上市后填补了该领域的空白。公司下一阶段关键性产品一治疗肝纤维化的F351(轻尼酮)被药审中心认定为“突破性治疗药物”有望成为全球首款获批治疗慢性乙肝(CHB)相关纤维化的药物。 公司将通过艾思瑞积累的从自主开发到商业化成功的完整经验丰富并推进产品管线,将治疗领域逐渐拓宽至其他器官纤维化,研究和开发治疗肺纤维化、肝纤维化及肾纤维化的创新药品,为更多器官纤维化患者带来新希望。
| 今开：11.01 | 昨收：10.76 |
| 最高：11.5 | 最低：11.01 |
| 涨停价： | 跌停价： |
| 总市值：957713299 |
SeekingBiotech05-23 14:06
F230片 北京康蒂尼药业股份有限公司 肺动脉高压
Gyre Therapeutics(GYRE)05-31 04:15
$Gyre Therapeutics(GYRE)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001140361-24-028107 Act: 33 Size: 1 MB 网页链接
Gyre Therapeutics(GYRE)05-31 04:05
$Gyre Therapeutics(GYRE)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001140361-24-028104 Act: 33 Size: 691 KB 网页链接
Gyre Therapeutics(GYRE)05-31 04:15
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001140361-24-028106 Act: 34 Size: 190 KB 网页链接
Gyre Therapeutics(GYRE)05-14 04:15
$Gyre Therapeutics(GYRE)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-058642 Act: 34 Size: 9 MB 网页链接
Gyre Therapeutics(GYRE)05-10 04:15
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-056893 Act: 34 Size: 448 KB 网页链接
Gyre Therapeutics(GYRE)05-08 20:05
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001140361-24-024799 Act: 34 Size: 202 KB 网页链接
Gyre Therapeutics(GYRE)05-03 06:25
$Gyre Therapeutics(GYRE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001140361-24-024125 Size: 13 KB 网页链接
Gyre Therapeutics(GYRE)05-02 04:55
$Gyre Therapeutics(GYRE)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-003294 Act: 33 Size: 6 KB 网页链接
Gyre Therapeutics(GYRE)04-29 20:55
$Gyre Therapeutics(GYRE)$ ARS Annual Report to Security Holders Accession Number: 0001140361-24-022725 Act: 34 Size: 1 MB 网页链接
SeekingBiotech05-23 14:06
F230片 北京康蒂尼药业股份有限公司 肺动脉高压查看全文
股市闲谈03-15 15:11
康蒂尼药业去年借壳上市之后一直没怎么发声，今年应该会有比较大的动作查看全文
Gyre Therapeutics(GYRE)02-15 06:25
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 2.02, 7.01, and 9.01 Accession Number: 0001140361-24-008051 Act: 34 Size: 1 MB 网页链接查看全文
Gyre Therapeutics(GYRE)02-15 02:25
$Gyre Therapeutics(GYRE)$ SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals Accession Number: 0000935836-24-000173 Act: 34 Size: 30 KB 网页链接查看全文
Gyre Therapeutics(GYRE)01-25 06:15
$Gyre Therapeutics(GYRE)$ SC 13D/A [Amend] General statement of acquisition of beneficial ownership Accession Number: 0001140361-24-003688 Act: 34 Size: 76 KB 网页链接查看全文
Gyre Therapeutics(GYRE)01-20 05:15
$Gyre Therapeutics(GYRE)$ 8-K/A [Amend] Current report, items 3.01, 5.02, and 9.01 Accession Number: 0001140361-24-002903 Act: 34 Size: 303 KB 网页链接查看全文
Gyre Therapeutics(GYRE)01-13 05:05
$Gyre Therapeutics(GYRE)$ 8-K/A [Amend] Current report, items 2.01 and 9.01 Accession Number: 0001140361-24-002118 Act: 34 Size: 2 MB 网页链接查看全文
Gyre Therapeutics(GYRE)2023-12-16 05:25
$Gyre Therapeutics(GYRE)$ 8-K Current report, item 5.02 Accession Number: 0001140361-23-057889 Act: 34 Size: 166 KB 网页链接查看全文
Gyre Therapeutics(GYRE)2023-12-07 05:05
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 7.01 and 9.01 Accession Number: 0001140361-23-056503 Act: 34 Size: 220 KB 网页链接查看全文
Gyre Therapeutics(GYRE)2023-11-30 05:05
$Gyre Therapeutics(GYRE)$ RW Registration Withdrawal Request Accession Number: 0001140361-23-055209 Act: NE Size: 24 KB 网页链接查看全文
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001140361-24-028106 Act: 34 Size: 190 KB 网页链接
$Gyre Therapeutics(GYRE)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001140361-24-028107 Act: 33 Size: 1 MB 网页链接
$Gyre Therapeutics(GYRE)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001140361-24-028104 Act: 33 Size: 691 KB 网页链接
$Gyre Therapeutics(GYRE)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0000950170-24-058642 Act: 34 Size: 9 MB 网页链接
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-056893 Act: 34 Size: 448 KB 网页链接
$Gyre Therapeutics(GYRE)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0001140361-24-024799 Act: 34 Size: 202 KB 网页链接
$Gyre Therapeutics(GYRE)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001140361-24-024125 Size: 13 KB 网页链接
$Gyre Therapeutics(GYRE)$ 144 Report of proposed sale of securities Accession Number: 0001950047-24-003294 Act: 33 Size: 6 KB 网页链接
$Gyre Therapeutics(GYRE)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0001140361-24-022723 Act: 34 Size: 1 MB 网页链接
$Gyre Therapeutics(GYRE)$ DEF 14A Other definitive proxy statements Accession Number: 0001140361-24-022721 Act: 34 Size: 2 MB 网页链接